Please assess the completion status of the following clinical trial:

Trial Title: Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hyperkalemia, defined as K+ ≥5.8 obtained via local laboratory or point-of-care testing~* Written informed consent obtained.~Exclusion Criteria:~1. Clinically significant arrhythmia, defined as any arrhythmia requiring ongoing IV antiarrhythmic therapy.~2. Patients who are hemodynamically unstable, defined as mean arterial pressure ≤65 mmHg or heart rate ≤40 beats per minute or ≥125 beats per minute at time of screening~3. Hyperkalemia solely due to overdose on potassium supplements~4. Known bowel obstruction~5. Subjects currently being treated with or having taken potassium binders (e.g., patiromer, sodium or calcium polystyrene sulfonate or sodium zirconium cyclosilicate) in the 7 days prior to baseline~6. Subjects expected to receive dialysis during the first 6 hours of the study treatment period~7. Known hypersensitivity to patiromer or its ingredients~8. Participation in any other investigational device or drug study \<30 days prior to screening, or current treatment with other investigational agent(s)~9. Inability to consume the investigational product or, in the opinion of the Investigator unsuitable for study participation~10. Life expectancy of less than 6 months~11. Patients with automatically timed medication orders to control potassium in the ED~12. Patient is known to be pregnant or breastfeeding~13. An employee of investigational site or sponsors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Veltassa (Type: ACTIVE_COMPARATOR): 3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department
- Placebo (Type: PLACEBO_COMPARATOR): 3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department

Based on this trial design, predict the completion outcome and termination type (if applicable).